Filing Flows › Ocular Therapeutix (OCUL) › Q3 2026
Ocular Therapeutix (OCUL) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 9, 2026
Ocular Therapeutix (OCUL) reported revenue of $12.9M for the third quarter 2026 (Q3 2026), -11% from a year earlier and -4% from the quarter before. Operating margin was -760.1%, net loss $94.8M (736.2% of revenue).
Ocular Therapeutix, Q3 2026: revenue $12.9M (-12% year over year), operating margin -760.1%, net loss $94.8M, operating cash flow −$65.6M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $12.9M | -4% | -11% |
| Operating profit | −$97.9M | — | — |
| Net earnings | −$94.8M | — | — |
| Operating cash flow | −$65.6M | — | — |
What changed
Revenue was $12.9M in Q3 2026, down 11% year over year and down 4% from the previous quarter.
Operating costs exceeded revenue by $97.9M, an operating margin of -760.1%. Total costs grew 33% against a revenue fall of 11%. The fastest-growing cost line was Research & development (+43%). The quarter ended with a net loss of $94.8M, wider than the previous quarter's $78.8M loss.
Operating cash flow was −$65.6M. Non-cash charges added back $2.4M of depreciation and amortization and $15.1M of share-based compensation. Working capital and other items added $11.7M. Capital expenditures of $3.0M exceeded it, leaving free cash flow of −$68.7M.
Questions
What was Ocular Therapeutix's revenue in the third quarter 2026?
Ocular Therapeutix (OCUL) reported revenue of $12.9M for the third quarter 2026 (Q3 2026), -11% from a year earlier and -4% from the quarter before.
Was Ocular Therapeutix profitable in the third quarter 2026?
Operating loss was $97.9M (-760.1% of revenue) and net loss $94.8M.
Source: Ocular Therapeutix 10-Q on SEC EDGAR.